Loading stock analysis…
Evidence Synthesis
Last synthesized: 22 Aug 2026, 00:02
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
3BBLACKBIO's quarterly performance showed a significant acceleration in its gross margin, up to 75.29%, from 21.44%.
The company's revenue growth year-over-year also accelerated, increasing by from -29%. On the other hand, its marginal operating leverage decelerated, falling to from 36.25%. The stock price rose by from its previous close. Additionally, the company's daily trading volume increased by 0.111% to . The close price also rose by 0.042% to .
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 75.29 % | 21.44 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 21.44 % | 36.25 | ▼ |
| REVENUE_GROWTH_YOY | 50.6 % | -29 | ▲ |
| PRICE_CHANGE_PERCENT | 4.465 % | — | - |
| DAILY_VOLUME | 18,551 shares | 16,547 | ▲ |
| CLOSE_PRICE | 1,202.5 INR | 1,151.1 | ▲ |